The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
In this review we describe the evidence supporting the main mechanisms underlying IFN-alpha anticancer effects using both preclinical and clinical findings; moreover, we focus on the results of IFN-alpha for the treatment of patients with high-risk cutaneous melanoma, one of the malignancies most resistant to conventional chemotherapy.
Keywords: Anticancer; Dendritic Cells; FLC; IFN; IFN-DCs; IFN-alpha/beta; IFN-alpha2b thera; Immunity; Interferon alpha; MHC; Philadelphia chromosome; RCT; TS/A; [GM-CSF]; adenoviral; cancer; carcinoma; chronic myeloid leukemia; gancyclovir; gangliosides; leukemia; lymphomas; melanoma; mixed-lymphocyte reaction; molecular biology; therapy; thymidine kinase; tumor
Document Type: Research Article
Publication date: 2010-10-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.